Agilent Technologies

Agilent Technologies

Signal active

Investment Firm

Overview

Agilent provides laboratory solutions to meet the needs of analytical scientists and clinical researchers worldwide. Agilent works closely with customers to help address global trends that impact human health and the environment and to anticipate future scientific needs. Agilent's solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management.

Highlights

Founded

1999

Industry

Biotechnology

Employees

10001+

Investment

37

Lead Investment

6

Exits

10

Stages

Private Equity, Early Stage Venture, Late Stage Venture, Seed

Investor Type

N/A

Location

Santa Clara, California, United States, North America

Contact Information

Social

Profile Resume

Agilent Technologies, established in 1999 and headquartered in United States, North America., specializes in Private Equity, Early Stage Venture, Late Stage Venture, Seed investments across Biotechnology, Manufacturing, Genetics, Developer Tools, Service Industry, Optical Communication, Financial Services, Venture Capital, Finance, Angel Investment. The organization boasts a portfolio of 37 investments, with an average round size of $34.4M and 10 successful exits. Their recent investments include Gen9, Big Bear Networks, Sequoia Capital, Oak Investment Partners, Accel. The highest investment round they participated in was $129.4B. Among their most notable exits are Gen9 and Big Bear Networks. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.

Employees

imagePlace Andy Neilson

Andy Neilson

R&D Scientist

imagePlace Al Bukys

Al Bukys

Director of Engineering

imagePlace Paul Beresford

Paul Beresford

VP and GM of CDx

imagePlace Mike McMullen

Mike McMullen

President & CEO

imagePlace Darlene Solomon

Darlene Solomon

CTO and Senior Vice President

imagePlace Paul Davies

Paul Davies

SaaS Architecture Manager

Investment portfolio

Agilent Technologies has made 37 investments. Their most recent investment was on Jun 27, 2024, when RareCyte raised $20.0M.

Agilent Technologies has made 5 diversity investments. Their most recent diversity investment was on Jul 13, 2021, when Mobilion Systems raised $60.0M.

investments

37

Diversity investments

5

Lead investments

6

Number of exits

10

Investments

37

Annouced DateOrganization NameIndustryMoney Raised
Sep 06, 2023
Halo X Ray Technologies Halo X Ray Technologies
Industrial Automation2.5M
Apr 03, 2024
Biofidelity Biofidelity
Biotechnology24.0M
May 14, 2024
Elegen Elegen
Biotechnology35.0M
Jun 27, 2024
RareCyte RareCyte
Biotechnology20.0M

Exits

10

Funding Timeline

Funding rounds

37

Investors

0

Funds

0

Funding Rounds

37

Agilent Technologies has raised 37 rounds. Their latest funding was raised on Jun 27, 2024 from a Venture Round - RareCyte round.

Annouced DateTransaction NameNumber of InvestorsMoney RaisedLead Investor
Sep 06, 2023
Series A - Halo X Ray Technologies Series A - Halo X Ray Technologies
-2.5M-
Apr 03, 2024
Venture Round - Biofidelity Venture Round - Biofidelity
-24.0M-
May 14, 2024
Series B - Elegen Series B - Elegen
-35.0M-
Jun 27, 2024
Venture Round - RareCyte Venture Round - RareCyte
-20.0M-

Investors

1

Investor NameLead InvestorFunding RoundMoney Raised
-No
Post-IPO Debt - Agilent Technologies
500.0M

Fund raised

2

Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.

Annouced DateFund NameMoney Raised
May 10, 2013
fund image OTPPLESS
1.0M
May 11, 2013
fund image OTPPLESS
1.0M

Invest in industries

Recent Activity

News

Sep 13, 2024

Yahoo Finance - Those who invested in Agilent Technologies (NYSE:A) five years ago are up 85%

News

Aug 21, 2024

SeekingAlpha - Agilent Technologies Non-GAAP EPS of $1.32 beats by $0.06, revenue of $1.58B beats by $20M

News

Aug 20, 2024

Yahoo Finance - Agilent Technologies (NYSE:A) jumps 5.8% this week, though earnings growth is still tracking behind five-year shareholder returns

News

Jul 23, 2024

Genetic Engineering and Biotechnology News - Agilent to Acquire Biovectra for $925M, Expanding CDMO Portfolio

News

Jul 22, 2024

Genetic Engineering and Biotechnology News - Agilent to Acquire Biovectra for $925M, Expanding CDMO Portfolio

News

Jul 22, 2024

Endpoints News - Agilent Technologies to acquire CDMO Biovectra for $925M